A randomized trial of the beta-adrenergic antagonist carvedilol in chronic kidney disease

Phase 3

• Conditions: Chronic kidney disease at stage of 3, 4 and 5

• Registration Number: JPRN-UMIN000001003
• Lead Sponsor: Rokko Island Hospital-Clinical Research Committee

Brief Summary

Renoprotective efficacy of carvedilol, presented at theAnnual scientific meeting of American Society of nephrology in 2007 (SA-FC039).

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2007-11-01
• Study Start: 2008-02-22
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

Exclusion criteria were: immediate need for renal replacement therapy; treatment-resistant oedema; need for treatment with corticosteroids, non-steroidal anti-inflammatory drugs, or immunosuppressive drugs; proteinuria greater than 10 g per day and hypoalbuminaemia less than 28 g/L (normal range 36–50 g/L); renovascular hypertension; malignant hypertension, myocardial infarction, or cerebrovascular accident in the year preceding the trial; severe peripheral vascular disease; severe congestive heart failure (NYHA III–IV); chronic hepatic disease (rise of serum aminotransferase concentration); connective-tissue disease; obstructive uropathy; cancer; chronic pulmonary disease; drug or alcohol misuse; pregnancy; and breastfeeding.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A combined renal outcome of a doubling of serum creatinine concentration and/or end-stage renal disease

Secondary Outcome Measures

Name	Time	Method
1) estimated glomerular filtration rate 2) dairy proteinuria excretion 3) blood pressure, heart rate 4) cardiovascular events 5) cardiac ultrasound 6) blood neurohormones, hANP, and BNP levels